Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more
Genmab A/S - Asset Resilience Ratio
Genmab A/S (GNMSF) has an Asset Resilience Ratio of 23.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Genmab A/S's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Genmab A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.65 Billion | 23.5% |
| Total Liquid Assets | $1.65 Billion | 23.50% |
Asset Resilience Insights
- Good Liquidity Position: Genmab A/S maintains a healthy 23.50% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Genmab A/S Industry Peers by Asset Resilience Ratio
Compare Genmab A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Genmab A/S (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Genmab A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 24.54% | $11.24 Billion | $45.81 Billion | -13.06pp |
| 2023-12-31 | 37.60% | $13.27 Billion | $35.29 Billion | -3.67pp |
| 2022-12-31 | 41.27% | $12.43 Billion | $30.12 Billion | -0.88pp |
| 2021-12-31 | 42.15% | $10.38 Billion | $24.63 Billion | +0.44pp |
| 2020-12-31 | 41.71% | $8.82 Billion | $21.14 Billion | -7.28pp |
| 2019-12-31 | 48.99% | $7.42 Billion | $15.14 Billion | -16.88pp |
| 2018-12-31 | 65.87% | $5.57 Billion | $8.46 Billion | +4.15pp |
| 2017-12-31 | 61.72% | $4.08 Billion | $6.60 Billion | -7.29pp |
| 2016-12-31 | 69.01% | $3.61 Billion | $5.24 Billion | +1.89pp |
| 2015-12-31 | 67.12% | $2.62 Billion | $3.90 Billion | -13.17pp |
| 2014-12-31 | 80.28% | $2.30 Billion | $2.87 Billion | +0.07pp |
| 2013-12-31 | 80.21% | $1.39 Billion | $1.73 Billion | -4.66pp |
| 2012-12-31 | 84.87% | $1.44 Billion | $1.69 Billion | +18.69pp |
| 2011-12-31 | 66.19% | $1.04 Billion | $1.56 Billion | +3.79pp |
| 2010-12-31 | 62.39% | $1.55 Billion | $2.48 Billion | +25.62pp |
| 2009-12-31 | 36.77% | $816.91 Million | $2.22 Billion | -15.15pp |
| 2008-12-31 | 51.92% | $1.69 Billion | $3.26 Billion | -38.05pp |
| 2007-12-31 | 89.97% | $3.56 Billion | $3.96 Billion | +18.20pp |
| 2006-12-31 | 71.77% | $1.30 Billion | $1.80 Billion | +8.18pp |
| 2005-12-31 | 63.60% | $871.56 Million | $1.37 Billion | +5.51pp |
| 2004-12-31 | 58.09% | $738.86 Million | $1.27 Billion | -- |